A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

850

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Pumitamig
DRUG: Durvalumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]